Silence Therapeutics (SLN) Shares Outstanding (Weighted Average) (2018 - 2026)

Silence Therapeutics' Shares Outstanding (Weighted Average) history runs 9 years deep, the most recent figure standing at $141.7 million for Q1 2026.

• In Q1 2026, Shares Outstanding (Weighted Average) changed 0.02% year-over-year to $141.7 million; the TTM figure through Mar 2026 stood at $141.7 million (changed 0.02% YoY), while the FY2025 annual figure was $141.7 million, up 2.12% from the prior year.
• Shares Outstanding (Weighted Average) came in at $141.7 million for Q1 2026 at Silence Therapeutics, roughly flat from $141.7 million in the prior quarter.
• In the past five years, Shares Outstanding (Weighted Average) ranged from a high of $183.5 million in Q3 2024 to a low of $5.7 million in Q2 2022.
• A 5-year average of $97.6 million and a median of $138.8 million in 2024 frame the typical range for Shares Outstanding (Weighted Average).
• Across the five-year window, Shares Outstanding (Weighted Average) soared 2447.33% in 2024 and declined 22.77% in 2025, its largest moves.
• Silence Therapeutics' Shares Outstanding (Weighted Average) stood at $113.3 million in 2022, then advanced by 21.91% to $138.1 million in 2023, then rose by 0.46% to $138.8 million in 2024, then rose by 2.12% to $141.7 million in 2025, then gained by 0.01% to $141.7 million in 2026.
• According to Business Quant data, Shares Outstanding (Weighted Average) over the past three periods registered $141.7 million, $141.7 million, and $141.7 million for Q1 2026, Q4 2025, and Q3 2025 respectively.

Peer Comparison